The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium
Open accessAbstract
Angiopoietin 2 (Ang2) was originally shown to be a competitive antagonist for Ang1 of the receptor tyrosine kinase Tie2 in endothelial cells (ECs). Since then, reports have conflicted on whether Ang2 is an agonist or antagonist of Tie2. Here we show that Ang2 functions as an agonist when Ang1 is absent but as a dose-dependent antagonist when Ang1 is present. Exogenous Ang2 activates Tie2 and the promigratory, prosurvival PI3K/Akt pathway in ECs but with less potency and lower affinity than exogenous Ang1. ECs produce Ang2 but not Ang1. This endogenous Ang2 maintains Tie2, phosphatidylinositol 3-kinase, and Akt activities, and it promotes EC survival, migration, and tube formation. However, when ECs are stimulated with Ang1 and Ang2, Ang2 dose-dependently inhibits Ang1-induced Tie2 phosphorylation, Akt activation, and EC survival. We conclude that Ang2 is both an agonist and an antagonist of Tie2. Although Ang2 is a weaker agonist than Ang1, endogenous Ang2 maintains a level of Tie2 activation that is critical to a spectrum of EC functions. These findings may reconcile disparate reports of Ang2's effect on Tie2, impact our understanding of endogenous receptor tyrosine kinase signal transduction mechanisms, and affect how Ang2 and Tie2 are targeted under conditions such as sepsis and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Ang1 and Ang2 are the best-characterized ligands of Tie2 and were originally shown to be agonistic and antagonistic, respectively (14, 29, 42, 45).”
BackgroundAngiopoietin-2, a Natural Antagonist for Tie2 That Disrupts in vivo Angiogenesis
Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., et al. (1997) · Science · doi:10.1126/science.277.5322.55 · Cited by 3,570
Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis
Suri, C., Jones, P. F., Patan, S., Bartunkova, S., Maisonpierre, P. C., Davis, S., Sato, T. N., & Yancopoulos, G. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81813-9 · Cited by 2,847
Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning
Davis, S., Aldrich, T. H., Jones, P. F., Acheson, A., Compton, D. L., Jain, V., Ryan, T. E., Bruno, J., Radziejewski, C., Maisonpierre, P. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81812-7 · Cited by 1,989 · cited 2×
“Through the phosphatidylinositol 3-kinase (PI3K)-Akt pathway and others, Ang1 exerts prosurvival, antipermeability, and anti-inflammatory effects on endothelial cells (ECs) ( 9 , 13, 16, 24, 27, 30, 43).”
BackgroundLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M. H., Jackson, D., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00217-4 · Cited by 1,018
Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J.-Å., & Nilsson, S. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.105 · Cited by 779
Fiedler, U., Scharpfenecker, M., Koidl, S., Hegen, A., Grunow, V., Schmidt, J. M., Kriz, W., Thurston, G., & Augustin, H. G. (2004) · Blood · doi:10.1182/blood-2003-10-3685 · Cited by 742
Excess Circulating Angiopoietin-2 May Contribute to Pulmonary Vascular Leak in Sepsis in Humans
Parikh, S. M., Mammoto, T., Schultz, A., Yuan, H.-T., Christiani, D., Karumanchi, S. A., & Sukhatme, V. P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030046 · Cited by 527
Self-citationGamble, J. R., Drew, J., Trezise, L., Underwood, A., Parsons, M., Kasminkas, L., Rudge, J., Yancopoulos, G., & Vadas, M. A. (2000) · Circulation Research · doi:10.1161/01.res.87.7.603 · Cited by 505
Cited by
PI3K/AKT/mTOR Pathway in Angiogenesis
Karar, J., & Maity, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00051 · Cited by 1,461
Pericytes of the neurovascular unit: key functions and signaling pathways
Sweeney, M. D., Ayyadurai, S., & Zlokovic, B. V. (2016) · Nature Neuroscience · doi:10.1038/nn.4288 · Cited by 1,125
Nanocomposite scaffolds for accelerating chronic wound healing by enhancing angiogenesis
Nosrati, H., Aramideh Khouy, R., Nosrati, A., Khodaei, M., Banitalebi-Dehkordi, M., Ashrafi-Dehkordi, K., Sanami, S., & Alizadeh, Z. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00755-7 · Cited by 720
Fagiani, E., & Christofori, G. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.08.018 · Cited by 676
Therapeutic targeting of the angiopoietin–TIE pathway
Saharinen, P., Eklund, L., & Alitalo, K. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.278 · Cited by 620
Molecular pathogenesis of retinal and choroidal vascular diseases
Campochiaro, P. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.002 · Cited by 545
Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
Akwii, R. G., Sajib, M. S., Zahra, F. T., & Mikelis, C. M. (2019) · Cells · doi:10.3390/cells8050471 · Cited by 543
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., Bartol, A., Kienast, Y., Vettel, C., Loos, E. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58832 · Cited by 479
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468
Retinal vasculature development in health and disease
Selvam, S., Kumar, T., & Fruttiger, M. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.11.001 · Cited by 353
Pericyte-expressed Tie2 controls angiogenesis and vessel maturation
Teichert, M., Milde, L., Holm, A., Stanicek, L., Gengenbacher, N., Savant, S., Ruckdeschel, T., Hasanov, Z., Srivastava, K., Hu, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms16106 · Cited by 348
Coffelt, S. B., Tal, A. O., Scholz, A., De Palma, M., Patel, S., Urbich, C., Biswas, S. K., Murdoch, C., Plate, K. H., Reiss, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0012 · Cited by 343
Tie1 controls angiopoietin function in vascular remodeling and inflammation
Korhonen, E. A., Lampinen, A., Giri, H., Anisimov, A., Kim, M., Allen, B., Fang, S., D’Amico, G., Sipilä, T. J., Lohela, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84923 · Cited by 283
Mechanisms Regulating Endothelial Permeability
Sukriti, S., Tauseef, M., Yazbeck, P., & Mehta, D. (2014) · Pulmonary Circulation · doi:10.1086/677356 · Cited by 283
Wei, Y., Jiang, Y., Zou, F., Liu, Y., Wang, S., Xu, N., Xu, W., Cui, C., Xing, Y., Liu, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217002110 · Cited by 274
Plasma Angiopoietin-2 Predicts the Onset of Acute Lung Injury in Critically Ill Patients
Agrawal, A., Matthay, M. A., Kangelaris, K. N., Stein, J., Chu, J. C., Imp, B. M., Cortez, A., Abbott, J., Liu, K. D., & Calfee, C. S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201208-1460oc · Cited by 272
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
Holopainen, T., Saharinen, P., D’Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Heloterä, H., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs009 · Cited by 216
Srivastava, K., Hu, J., Korn, C., Savant, S., Teichert, M., Kapel, S. S., Jugold, M., Besemfelder, E., Thomas, M., Pasparakis, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.11.005 · Cited by 140
Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization
Leppänen, V.-M., Saharinen, P., & Alitalo, K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616166114 · Cited by 127
Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality
David, S., Ghosh, C. C., Kümpers, P., Shushakova, N., Van Slyke, P., Khankin, E. V., Karumanchi, S. A., Dumont, D., & Parikh, S. M. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00459.2010 · Cited by 96
Self-citationActivated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function
Minhas, N., Xue, M., Fukudome, K., & Jackson, C. J. (2010) · The FASEB Journal · doi:10.1096/fj.09-134445 · Cited by 94
Li, Z., Korhonen, E. A., Merlini, A., Strauss, J., Wihuri, E., Nurmi, H., Antila, S., Paech, J., Deutsch, U., Engelhardt, B., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130308 · Cited by 52
Characterization of ANGPT2 mutations associated with primary lymphedema
Leppänen, V.-M., Brouillard, P., Korhonen, E. A., Sipilä, T., Jha, S. K., Revencu, N., Labarque, V., Fastré, E., Schlögel, M., Ravoet, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8013 · Cited by 49
Richter, S., Qin, N., Pacak, K., & Eisenhofer, G. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-411512-5.00014-2 · Cited by 42
“Generally ANG2 is a weaker agonist for the TIE2 receptor, and in the presence of ANG1 it actually inhibits its actions; but if ANG1 is absent ANG2 activates the TIE2 receptor and downstream signalling of PI3K and AKT (Yuan et al., 2009)(Figure 1).”
BackgroundInfluentialMinhas, N., Xue, M., & Jackson, C. J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2440-6 · Cited by 31
Dimerization of Tie2 mediated by its membrane-proximal FNIII domains
Moore, J. O., Lemmon, M. A., & Ferguson, K. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617800114 · Cited by 30
Im, J. H., Tapmeier, T., Balathasan, L., Gal, A., Yameen, S., Hill, S., Smart, S., Noterdaeme, O., Kelly, M., Brady, M., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27677 · Cited by 25
Metadata
- Authors
- Yuan, H. T., Khankin, E. V., Karumanchi, S. A., & Parikh, S. M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2009-04-01
- Volume
- 29
- Issue
- 8
- Pages
- 2011-2022
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W1976019207
- Cited by
- 373
- References
- 49
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.